Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Craniopharyngioma × tovorafenib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Melanoma 4 Low-grade Glioma 3 Pancreatic Neoplasms 2 Neoplasms 2 Glioma 2 Colorectal Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Astrocytoma 2 Urinary Bladder Neoplasms 1 Thyroid Cancer, Papillary 1 Noonan Syndrome 5 1 Leukemia, Hairy Cell 1 Diffuse Intrinsic Pontine Glioma 1 Craniopharyngioma 1 Brain Neoplasms 1 Advanced Nonhematologic Malignancies 1

Interventions

Surgical Procedures, Operative 3 Exenatide 3 tocilizumab 2 Temozolomide 2 Surveys and Questionnaires 2 Mental Status and Dementia Tests 2 Magnetic Resonance Spectroscopy 2 Donepezil 2 trametinib 1 tozuleristide 1 tovorafenib 1 temsirolimus 1 gallium Ga 68 dotatate 1 entinostat 1 dabrafenib 1 cobimetinib 1 carboxyamido-triazole 1 binimetinib 1 antineoplaston AS 2-1 1 antineoplaston A10 1 anlotinib 1 Verteporfin 1 Vemurafenib 1 Tumor Burden 1 Transurethral Resection of Bladder 1 Thalidomide 1 Radiotherapy, Intensity-Modulated 1 Radiotherapy, Image-Guided 1 Radiotherapy, Conformal 1 Radiotherapy 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05465174 2026-03-09

PNOC029

University of California, San Francisco

Phase 2 Recruiting

Craniopharyngioma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡